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A B S T R A C T
Purpose
The NSABP (National Surgical Adjuvant Breast and Bowel Project) B-24 study demonstrated
significant benefit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after
lumpectomy and radiation. Patients were enrolled without knowledge of hormone receptor status.
The current study retrospectively evaluated the relationship between receptors and response
to tamoxifen.
Patients and Methods
Estrogen (ER) and progesterone receptors (PgR) were evaluated in 732 patients with DCIS (41%
of original study population). An experienced central laboratory determined receptor status in all
patient cases with available paraffin blocks (n  449) by immunohistochemistry (IHC) using
comprehensively validated assays. Results for additional patients (n  283) determined by various
methods (primarily IHC) were available from enrolling institutions. Combined results were
evaluated for benefit of tamoxifen by receptor status at 10 years and overall follow-up (median,
14.5 years).
Results
ER was positive in 76% of patients. Patients with ER-positive DCIS treated with tamoxifen (v
placebo) showed significant decreases in subsequent breast cancer at 10 years (hazard ratio [HR],
0.49; P  .001) and overall follow-up (HR, 0.60; P  .003), which remained significant in
multivariable analysis (overall HR, 0.64; P  .003). Results were similar, but less significant, when
subsequent ipsilateral and contralateral, invasive and noninvasive, breast cancers were considered
separately. No significant benefit was observed in ER-negative DCIS. PgR and either receptor
were positive in 66% and 79% of patients, respectively, and in general, neither was more
predictive than ER alone.
Conclusion
Patients in NSABP B-24 with ER-positive DCIS receiving adjuvant tamoxifen after standard therapy
showed significant reductions in subsequent breast cancer. The use of adjuvant tamoxifen should
be considered for patients with DCIS.
J Clin Oncol 30:1268-1273. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Ductal carcinoma in situ (DCIS) was gradually
recognized as a disease distinct from invasive
breast cancer (IBC) during the early 20th cen-
tury.1,2 Between then and the introduction of
screening mammography 70 to 80 years later,
DCIS accounted for fewer than 5% of newly diag-
nosed breast cancers.3-6 Since the introduction
and widespread use of screening mammography
in the United States, the incidence of DCIS has
increased dramatically, and today it accounts for
20% to 30% of all breast cancers.3,5,6
In the not too distant past, the standard treat-
ment for DCIS was mastectomy and complete axil-
lary dissection, which eradicated the disease, but at
the high cost of disfiguring surgery.4,7,8 Local exci-
sion largely replaced this radical approach, and to-
day lumpectomy is the standard of care for the
majority of patients with DCIS.9-11 Early experience
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with lumpectomy alone was disappointing, with local recurrence rates
of 30% or more, mainly because of the difficulty of obtaining clear
surgical margins.4,12-16 Adjuvant radiotherapy was added to lumpec-
tomy to sterilize occult residual tumor.17-19 The seminal NSABP (Na-
tional Surgical Adjuvant Breast and Bowel Project) B-17 DCIS trial
demonstrated that the addition of radiotherapy reduced the relative
risk of local recurrence by 61%, although 13% of patients still eventu-
ally developed an ipsilateral recurrence, comparable to patients with
IBC treated in a similar manner.20,21 As a result of its success in treating
IBCs,22,23 the NSABP conducted its B-24 clinical trial to evaluate
adjuvant tamoxifen in DCIS after lumpectomy and radiation. This
trial demonstrated an additional 37% reduction in relative risk of local
recurrence and a decrease in contralateral breast cancer of comparable
magnitude.24 Results were similar in the United Kingdom-ANZ
(United Kingdom, Australia, and New Zealand) trial, which also eval-
uated the efficacy of adjuvant tamoxifen in DCIS.25
We now know that the benefit of tamoxifen in treating IBC is
essentially restricted to estrogen receptor (ER) –positive and/or pro-
gesterone receptor (PgR) –positive disease, consistent with the bio-
logic mechanism of action of the drug.26 B-24 was initiated before this
relationship was firmly established, and receptor status was not in-
volved in patient enrollment. The purpose of the current study was to
evaluate retrospectively ER and PgR and their relationships to re-
sponse to adjuvant tamoxifen in the B-24 trial.
PATIENTS AND METHODS
Study Population
The study samples were derived from patients enrolled onto NSABP
Protocol B-24,24 in which 1,804 women with DCIS were randomly assigned to
placebo (n  902) or tamoxifen (n  902) after lumpectomy and local
radiotherapy (Fig 1). Briefly, local radiotherapy (50 Gy) was administered
beginning no later than 8 weeks after surgery. Adjuvant placebo or tamoxifen
therapy (10 mg twice daily) was initiated within 56 days of surgery and
continued for 5 years. Follow-up included physical examination every 6
months and annual mammography. Local recurrences were confirmed histo-
logically. Distant metastases were confirmed clinically and by radiology and/or
histology. End point information was based on data through the closure of
follow-up to the study on May 1, 2007, obtained and received by the NSABP
Biostatistical Center by June 8, 2007. The median time on study for patients in
the analysis cohort at this time was 14.5 years. Informed consent was required
for all participants. The protocol and consent forms were approved by the
National Institutes of Health and the institutional review boards of all partic-
ipating institutions.
ER and PgR results for this study were available in a subset of patients
(41%; n  732) enrolled onto the original clinical trial. This subset was
statistically similar to the remaining study population with regard to the
distribution of treatment (placebo v tamoxifen) and other available factors
including age, race, eligibility status, tumor size, and surgical margin status
(data not shown).
Evaluation of ER and PgR
Formalin-fixed paraffin-embedded tissue (FFPET) blocks of DCIS were
available for 449 patents and were used to determine ER and PgR status by
immunohistochemistry (IHC) in an experienced central laboratory. The IHC
assays used mouse monoclonal antibodies 6F11 for ER (Novacastra, Burlin-
game, CA) and 1294 for PgR (Dako, Carpenteria, CA) and were comprehen-
sively validated in several previous studies of IBCs.27-30 The Allred score was
used to estimate the proportion and intensity of positive cells (range, 0 to 8),
and scores of 3 or greater were defined as clinically positive.28,30 Representative
examples of positive and negative IHC results for ER in DCIS are shown in
Figure 2.
ER and PgR results from laboratories used by enrolling institutions were
available for an additional 283 patients, although FFPET blocks were not
available for central laboratory testing for those patients. These results were
determined by a variety of methods reflecting daily practice at each institution
(IHC, 62%; radio-labeled ligand binding assay, 24%; enzyme immunoassay,
5%; unknown, 9%). Local interpretations of results, which also varied meth-
odologically, were relied on to define positive and negative receptor status.
There were no significant differences in the proportions of patient cases eval-
uated in central versus outside laboratories regarding treatment (placebo v
tamoxifen), age, race, tumor size, surgical margin status, or the presence of
comedo necrosis (data not shown).
Patients randomly assigned
(N = 1,804)
Placebo
(n = 902)
Tamoxifen
(n = 902)
Patients with follow-up
(n = 900)
Patients with follow-up
(n = 899)
Patients with sufficient
tissue for ER/PgR assessment
(analyzed; n = 368)
Patients with sufficient
tissue for ER/PgR assessment
(analyzed; n = 364)
Fig 1. CONSORT diagram summarizing the random assignment of patients in
the clinical trial and distribution of patient cases available for this study. ER,
estrogen receptor; PgR, progesterone receptor.
BA
Fig 2. Representative examples of estro-
gen receptor (ER) expression in ductal
carcinoma in situ (DCIS) determined by
immunohistochemistry. (A) Low-grade
DCIS, strongly ER positive (Allred score,
5  3  8/8); (B) high-grade DCIS, ER
negative (Allred score, 0/8).
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Statistical Analyses
The primary end point of analyses in this study was time to the occur-
rence of any breast cancer as a first event subsequent to the original diagnosis of
DCIS. Events included all local, regional, or distant recurrences and contralat-
eral breast cancers. Other primary cancers or deaths without breast cancer
were censored for the analysis. Secondary analyses included time to ipsilateral
and contralateral breast cancers (IBC and/or DCIS) as first events. Events used
in the analyses were medically reviewed and classified as being either invasive
or noninvasive (ie, DCIS).
Cox proportional hazards models were employed to make formal infer-
ences about group comparisons, and Kaplan-Meier curves were used to quan-
tify the percentage of patients who were free of recurrence over time. Both
unadjusted and adjusted Cox regression analyses were employed to quantify
hazard ratios (HRs) comparing the two treatment groups.31 Adjustments were
made for stratification of age at entry. Formal tests of treatment by ER status
interactions were also conducted. To further explore the variability of treat-
ment effects within ER subgroups, age-adjusted models were fitted. P values
associated with HRs were based on large sample approximations, except in
settings where expected events were quite rare (defined as  five in any
treatment group). For the latter cases, Fisher’s exact tests were employed by
assuming that the numbers of failures were governed by Poisson processes.31
Analyses were also performed to determine if significant treatment by stratifi-
cation variable interactions existed with respect to the end points.32 The
incidences of site-specific failures were calculated using cumulative incidence
curves.33-35 P values for treatment comparisons of cumulative incidence
curves were obtained using cause-specific hazard rates that adjusted for the
stratification variables.35
RESULTS
Distribution of Receptor Status and Other
Clinicopathologic Features
ER and PgR were positive in 76% and 66% of patients, respec-
tively, based on results from central and institutional results combined
(n 732). In patient cases with both ER and PgR results (n 714),
64% were ER positive/PgR positive, 13% were ER positive/PgR nega-
tive, 2% were ER negative/PgR positive, and 21% were ER negative/
PgR negative. Patients were almost evenly distributed between the
placebo and tamoxifen arms of the study (78% v 82%;P .30). There
were no significant differences in receptor status or other available and
potentially confounding factors between the two treatment groups,
including tumor size, margin status, comedo necrosis, age, race, and
method of detection (Table 1).
Table 1. Clinicopathologic Features of Patient Tumors With Known ER Status
Clinicopathologic
Variable
Patients (%)
P
Placebo
(n 368)
Tamoxifen
(n 364)
ER .30
Negative 26 22
Positive 74 78
PgR .11
Negative 36 31
Positive 61 68
Tumor size, cm .20
Unknown 3 2
 1 80 83
1-2 15 10
 2 4 5
Surgical margin .22
Unknown 2 1
Negative 71 70
Positive 16 13
Comedo necrosis .13
Unknown 13 17
Absent 43 50
Present 55 49
Age at entry, years .72
Unknown 2 1
 50 34 36
50-59 29 27
 60 37 37
Race .92
White 87 85
Black 6 7
Other 5 6
Unknown 2 2
Method of
detection .054
Mammography 83 77
Clinical 17 23
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
Comparing treatment groups.
Table 2. BC Development by ER Status and Type of DCIS Treatment in
Patients From NSABP B-24
Type of BC
Placebo
(n  368)
Tamoxifen
(n  364)
HR 95% CI P†No. % No. %
ER positive
Any
BC 84 31 58 20 0.58 0.415 to 0.81 .0015
IBC 52 19 33 12 0.53 0.34 to 0.82 .005
DCIS 32 12 25 9 0.66 0.39 to 1.12 .12
Ipsilateral
BC 47 17 39 14 0.68 0.44 to 1.03 .07
IBC 26 9 20 7 0.61 0.34 to 1.09 .10
DCIS 21 8 19 7 0.76 0.41 to 1.42 .39
Contralateral
BC 32 11 18 6 0.50 0.28 to 0.88 .02
IBC 21 8 12 4 0.51 0.25 to 1.03 .06
DCIS 11 4 6 2 0.47 0.17 to 1.27 .14
ER negative
Any
BC 25 27 20 25 0.88 0.49 to 1.59 .68
IBC 14 15 9 11 0.69 0.30 to 1.59 .38
DCIS 11 12 11 14 1.15 0.50 to 2.65 .75
Ipsilateral
BC 16 17 17 21 1.18 0.60 to 2.34 .63
IBC 6 6 7 9 1.24 0.42 to 3.70 .70
DCIS 10 11 10 13 1.15 0.48 to 2.75 .76
Contralateral
BC 7 7 3 4 0.46 0.12 to 1.80 .35
IBC 6 6 2 3 0.36 0.07 to 1.77 .29
DCIS 1 1 1 1 1.15 0.07 to 18.44 1.00
Abbreviations: BC, breast cancer; IBC, invasive breast cancer; DCIS, ductal
carcinoma in situ; ER, estrogen receptor; HR, hazard ratio; NSABP, National
Surgical Adjuvant Breast and Bowel Project.
HRs comparing tamoxifen with placebo adjusted by age at entry ( 49, 
50 years) over all follow-up time.
†P values for age-adjusted HRs determined based on large sample Wald
statistic from Cox proportional hazards models for all categories except
ER-negative contralateral breast cancer, which was determined by Fisher’s
exact test.
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Receptor Status and Response to Tamoxifen
Table 2 shows the risk of subsequent breast cancer in all patients
with DCIS stratified by treatment arm and ER status at overall follow-
up. Patients with ER-positive DCIS who received adjuvant tamoxifen
versus placebo showed significant reductions in any breast cancer
event (HR, 0.58; P  .001), any IBC (HR, 0.53; P  .005), and any
contralateral breast cancer (HR, 0.50; P .02). Reductions were also
observed for any DCIS, any ipsilateral cancer, ipsilateral IBC, ipsilat-
eral DCIS, contralateral IBC, and contralateral DCIS, but none were
statistically significant. Results were similar in analyses of patients
stratified by PgR and receptor (ER and/or PgR) status (Appendix
Table A1, online only) although overall, they were not more predictive
than when ER status was considered alone. Analyses at 10 years were
similar to those of overall follow-up (Appendix Table A1). No signif-
icant reductions were associated with ER-negative DCIS in any setting.
Figure 3 shows Kaplan-Meier curves comparing treatment
groups for ER-positive and -negative patients, demonstrating that the
reduction of subsequent breast cancer was restricted to patients with
receptor-positive DCIS treated with tamoxifen. In multivariable anal-
ysis (Table 3) of patients with available ER results, the only indepen-
dently significant predictors of subsequent breast cancer were
treatment status (tamoxifen v placebo; HR, 0.64; P .003) and age at
entry ( 49 v 50 years; HR, 0.61;P .001). Results were similar for
all patients in B-24.
DISCUSSION
The NSABP B-24 clinical trial demonstrated that adjuvant tamoxifen
reduces subsequent ipsilateral and contralateral breast cancers in
women with DCIS after lumpectomy and radiation.24 United
Kingdom-ANZ, the only other major randomized trial evaluating
tamoxifen in DCIS, failed to show a benefit in the lumpectomy plus
radiation arm of the study (comparable to B-24), although significant
benefit was observed in the lumpectomy plus tamoxifen alone arm.25
Tamoxifen has now been shown to significantly reduce subsequent
breast cancer in randomized clinical trials of patients with IBC (eg,
NSABP B-14),23,36 patients with DCIS (eg, NSABP B-24 and United
Kingdom-ANZ),24,25,37 and women who are at high risk for develop-
ing breast cancer (eg, NSABP P-1).38
Numerous studies and clinical trials over the past 25 years have
shown that the benefit of adjuvant tamoxifen in IBC is restricted to
patients with receptor-positive disease.36 The B-24 trial was initiated
before hormone receptor status was routinely evaluated in DCIS, and
Table 4. Cumulative Incidence of Developing Subsequent Breast Cancer
After Treatment at 10 Years in Patients With ER-Negative DCIS in
NSABP B-24
Event
Placebo
(%)
Tamoxifen
(%) HR 95% CI P†
Any breast cancer
Total 25 21 0.84 0.45 to 1.58 .59
Central 23 27 1.09 0.47 to 2.51 .85
Institutional 28 15 0.58 0.22 to 1.56 .28
Ipsilateral breast cancer
Total 18 21 1.06 0.51 to 2.20 .87
Central 19 24 1.23 0.48 to 3.20 .67
Institutional 16 18 0.84 0.27 to 2.66 .77
Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR,
hazard ratio; NSABP, National Surgical Adjuvant Breast and Bowel Project.
In patients determined to be ER negative (central laboratory testing: n  89
placebo, 48; tamoxifen, 41; institutional laboratory testing: n  85 placebo,
46; tamoxifen, 39]).
†P values determined based on large sample Wald statistic from Cox
proportional hazards models.
0
10-year P = .59
Overall P = .68
10-year P < .001
Overall P = .003
Placebo group (n = 94): 25 events
Tamoxifen group (n = 80): 20 events
No. at risk
Placebo 94 86 75 67 61 55 46 13
Tamoxifen 80 75 64 61 55 55 47 22
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Fig 3. Kaplan-Meier curves showing probability of any subsequent breast
cancer in patients with (A) estrogen receptor (ER) –negative and (B) ER-positive
ductal carcinoma in situ (DCIS) treated with adjuvant placebo versus tamoxifen.
Tamoxifen benefit (42% reduction in relative risk; P  .001) was restricted to
ER-positive DCIS.
Table 3. Multivariate Analyses of Patients With DCIS in NSABP B-24
Model Variable†
Time to Any Breast Cancer As
First Event
HR 95% CI P
Patients with known ER status (n  732)
Treatment (placebo‡ v tamoxifen) 0.643 0.481 to 0.861 .003
Age at entry, years ( 49‡ v  50) 0.609 0.457 to 0.812  .001
All patients with follow-up (n  1,799)
Treatment (placebo‡ v tamoxifen) 0.687 0.563 to 0.837  .001
Age at entry, years ( 49‡ v  50) 0.621 0.510 to 0.756  .001
Abbreviations: DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR,
hazard ratio; NSABP, National Surgical Adjuvant Breast and Bowel Project;
PgR, progesterone receptor.
End point, any subsequent breast cancer.
†The following variables were not significantly related to time to any breast
cancer in the multivariate analysis: clinical tumor size, ER status, PgR status,
comedo necrosis status, and margin status.
‡Baseline value used for comparison.
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patients were enrolled without this information. The current study
was undertaken to evaluate, retrospectively, the relationship be-
tween adjuvant tamoxifen and receptor status in DCIS, with the
expectation that the results would be similar to those in IBC. Indeed,
with prolonged follow-up, adjuvant tamoxifen was shown to signifi-
cantly reduce subsequent ipsilateral breast cancer only in patients with
ER-positive DCIS. Tamoxifen reduced contralateral breast cancer in
patients with ER-positive and -negative DCIS, as expected (ie, preven-
tion). No ipsilateral benefit was observed in ER-negative disease, em-
phasizing that tamoxifen must bind to functional ER to exert its
beneficial effect on pre-existing residual tumor cells.26,39
The current study was based on results from 732 patients with
DCIS and known receptor status. Receptors in a majority (61%) were
evaluated by IHC in an experienced central laboratory using compre-
hensively validated assays for ER and PgR.27-30,40 The remainder
(39%) were evaluated by various methods (the majority by IHC) in
institutional laboratories (FFPET blocks were not available for central
confirmation). All results were combined to increase the statistical
power of the study overall. However, a subset of patient cases (n 
102) was evaluated for ER by IHC in both central and institutional
laboratories, and agreement (positive v negative) was only 74.5%.
There was also a significant difference in the incidence of ER-negative
patient cases when the results from central and outside laboratories
were compared (20% v 30%; P  .002). Assuming the central
results are correct, this suggests a substantial rate of false negatives
from institutions. To investigate this issue, response to tamoxifen
was compared in patients with ER-negative DCIS determined in
central versus institutional laboratories (Table 4). Although it was
not statistically significant, there was an apparent benefit in ER-
negative patient cases determined by institutional laboratories (eg,
HR, 0.58; P .28 for any subsequent cancer), whereas no benefit
was observed in patients with central results (HR, 1.09; P .85 for
any cancer). These results are consistent with a false-negative rate
of 30% to 40% from institutional laboratories, which may be
responsible for the small apparent benefit observed in ER-negative
patient cases overall. Similar errors in receptor testing by IHC in
IBCs have been observed in laboratories around the world.41-44 In
response, the National Cancer Comprehensive Network, College
of American Pathologists, and American Society of Clinical Oncol-
ogists published guidelines to help improve the quality IHC testing
of hormone receptors in breast cancer.40,45
In summary, retrospective analyses of hormone receptors of pa-
tients enrolled onto the NSABP B-24 clinical trial showed a significant
benefit for adjuvant tamoxifen in patients with ER-positive DCIS after
standard therapy. This offers an additional therapeutic option for
patients and physicians to consider.
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